Why Investors Are Pumping the Brakes on NextCure’s Cancer Treatment
NextCure updated clinical results from its early stage cancer study at the Society for Immunotherapy of Cancer annual meeting. As a result, NextCure shares were crushed on Monday.
NextCure updated clinical results from its early stage cancer study at the Society for Immunotherapy of Cancer annual meeting. As a result, NextCure shares were crushed on Monday.
Lipocine shares absolutely plummeted on Monday after the firm announced that it received a Complete Response Letter from the FDA regarding its New Drug Application for Tlando.
Nektar Therapeutics shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune and other chronic inflammatory conditions.
Iovance Bio shares jumped on Friday after the firm announced results from its mid-stage metastatic melanoma study.
CVS released better than expected third-quarter financial results and upbeat guidance before the markets opened on Wednesday.
These four health care stocks look like solid picks for the fourth quarter and into 2020. They are also favorite picks from Raymond James analysts.
It's one thing to think that there is a value investor's dream awaiting in the shares of Walgreens Boots Alliance. It's another thing to consider that a member of the Dow Jones industrial average…
On a day that the Dow Jones industrials and S&P 500 just hit all-time highs, many companies are not exactly feeling the same love. Bluebird Bio is one such company.
The October 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
More people die every year from poor diet than from smoking, yet medical schools spend little time educating future doctors about nutrition.
On a day that the Dow Jones industrials and S&P 500 just hit all-time highs, many companies are not exactly feeling the same love. Bluebird Bio is one such company.
Wright Medical Group shares exploded on Monday after it was announced that the firm would be acquired by Stryker.
Redhill Bio shares jumped early on Monday after the firm announced that the FDA approved Talicia for the treatment of Helicobacter pylori infection in adults.
Biogen and Alkermes have announced that the FDA approved Vumerity for the treatment of relapsing forms of multiple sclerosis.
When Amgen released its third-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.66 in earnings per share (EPS) and $5.7 billion in revenue. That compared with consensus…